Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva receives positive opinion on leflunomide treatments

Teva receives positive opinion on leflunomide treatments

17th December 2010

Teva has been granted a positive regulatory opinion on two new generic medicines based on the compound leflunomide.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given its endorsement to Teva's application for marketing authorisation of the treatment Leflunomide Teva.

A generic version of the branded therapy Arava, Teva's drug is intended for use among adult sufferers of active rheumatoid arthritis.

In addition to this, the CHMP granted a positive opinion to a second leflunomide-based Teva treatment, Repso, which is intended to function against active psoriatic arthritis in addition to rheumatoid arthritis.

Arava was originally developed by Sanofi-aventis and is a disease-modifying antirheumatic drug that alleviates symptoms of the condition such as joint swelling and tenderness.

Last month, Teva announced that it will be entering the wound care market for the first time in January 2011 with the launch of PolyHeal, a product designed to treat chronic and hard-to-heal wounds.ADNFCR-8000103-ID-800298839-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.